Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine

• Published in: Clinical pharmacokinetics Vol. 60; no. 12; pp. 1509 - 1535
• Main Authors: Hermann, Robert, Krajcsi, Peter, Fluck, Markus, Seithel-Keuth, Annick, Bytyqi, Afrim, Galazka, Andrew, Munafo, Alain
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2021; Springer Nature B.V
• Subjects: Adenosine triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast cancer; Cancer therapies; Cladribine - pharmacology; Drug dosages; Drug interactions; Glycoproteins; Humans; Immune system; Internal Medicine; Keywords; Lymphocytes; Medicine; Medicine & Public Health; Membrane Transport Proteins; Multiple sclerosis; Neoplasm Proteins - metabolism; Permeability; Pharmacology/Toxicology; Pharmacotherapy; Proteins; Review; Review Article; Systematic review
• ISSN: 0312-5963; 1179-1926
• DOI: 10.1007/s40262-021-01065-3

Cladribine is a nucleoside analog that is phosphorylated in its target cells (B- and T-lymphocytes) to its active adenosine triphosphate form (2-chlorodeoxyadenosine triphosphate). Cladribine tablets 10 mg (Mavenclad ® ) administered for up to 10 days per year in 2 consecutive years (3.5-mg/kg cumulative dose over 2 years) are used to treat patients with relapsing multiple sclerosis. The ATP-binding cassette, solute carrier, and nucleoside transporter substrate, inhibitor, and inducer characteristics of cladribine are reviewed in this article. Available evidence suggests that the distribution of cladribine across biological membranes is facilitated by a number of uptake and efflux transporters. Among the key ATP-binding cassette efflux transporters, only breast cancer resistance protein has been shown to be an efficient transporter of cladribine, while P-glycoprotein does not transport cladribine well. Intestinal absorption, distribution throughout the body, and intracellular uptake of cladribine appear to be exclusively mediated by equilibrative and concentrative nucleoside transporters, specifically by ENT1, ENT2, ENT4, CNT2 (low affinity), and CNT3. Renal excretion of cladribine appears to be most likely driven by breast cancer resistance protein, ENT1, and P-glycoprotein. The latter may play a role despite its poor cladribine transport efficiency in view of the renal abundance of P-glycoprotein. There is no evidence that solute carrier uptake transporters such as organic anion transporting polypeptides, organic anion transporters, and organic cation transporters are involved in the transport of cladribine. Available in vitro studies examining the inhibitor characteristics of cladribine for a total of 13 major ATP-binding cassette, solute carrier, and CNT transporters indicate that in vivo inhibition of any of these transporters by cladribine is unlikely.